Close

KaloBios Pharma (KBIO) In Discussions with Shkreli Group About Continuing Operations

Go back to KaloBios Pharma (KBIO) In Discussions with Shkreli Group About Continuing Operations

KaloBios Pharma (KBIO) Continues Run-Up on Epic Short Squeeze

November 23, 2015 8:50 AM EST

KaloBios Pharma (NASDAQ: KBIO) is continuing higher pre-open Monday as the epic short... More

Macrocure (MCUR) Ramps Higher

November 20, 2015 10:47 AM EST

Macrocure (NASDAQ: MCUR) shares advanced Friday, rising 50%. Some traders tied the moved to recent gains in KaloBios Pharma (NASDAQ: KBIO) and Macrocure's 'thin' 6.2 million share float.

... More

Shock of Epic Short Squeeze in KaloBios Pharma (KBIO) Reverberates Across Wall Street

November 19, 2015 1:36 PM EST

The stock being talked about the most on trading desks today is KaloBios Pharma (NASDAQ: KBIO). After closing at around $2 per share, shares surged to as high as $21.05 (+953%) following a disclosure after the close from Turing Pharmaceuticals' Martin Shkreli, a man demonized for jacking up drug prices, that he accumulated 1.2 million shares.

$2... $4... $6... $10... $12... shares keep climbing as short sellers were left stunned.

You see, just... More

With Shkreli Spike, KaloBios Pharma (KBIO) May Be Overvalued by a Factor of 4

November 18, 2015 4:57 PM EST

The upside being seen in KaloBios Pharma (NASDAQ: KBIO) after the close (400%+) after Martin Shkreli... More

KaloBios Pharma (KBIO) Pops on Shkreli Insider Buy

November 18, 2015 4:25 PM EST

KaloBios Pharma (NASDAQ: KBIO) ripping higher as Martin Shkreli purchased shares.

Shkreli disclosed buying 1,211,115 shares from November 16, 2015-November 17, 2015. Prices paid ranged from $0.61-$2.43.

On November 13, 2015, KaloBios announced that it will wind down its operations and that it has engaged the Brenner... More